CA3094318A1 - Multivalent antibody - Google Patents
Multivalent antibody Download PDFInfo
- Publication number
- CA3094318A1 CA3094318A1 CA3094318A CA3094318A CA3094318A1 CA 3094318 A1 CA3094318 A1 CA 3094318A1 CA 3094318 A CA3094318 A CA 3094318A CA 3094318 A CA3094318 A CA 3094318A CA 3094318 A1 CA3094318 A1 CA 3094318A1
- Authority
- CA
- Canada
- Prior art keywords
- binding domain
- antibody
- multivalent antibody
- domain
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims abstract description 658
- 210000004027 cell Anatomy 0.000 claims description 313
- 239000000427 antigen Substances 0.000 claims description 252
- 102000036639 antigens Human genes 0.000 claims description 251
- 108091007433 antigens Proteins 0.000 claims description 251
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 112
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 112
- 241000282414 Homo sapiens Species 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 82
- 150000007523 nucleic acids Chemical class 0.000 claims description 73
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 69
- 235000001014 amino acid Nutrition 0.000 claims description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 52
- 150000001413 amino acids Chemical group 0.000 claims description 51
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 44
- 229920001184 polypeptide Polymers 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 43
- 210000004881 tumor cell Anatomy 0.000 claims description 42
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 241001465754 Metazoa Species 0.000 claims description 37
- 238000006467 substitution reaction Methods 0.000 claims description 35
- 239000012642 immune effector Substances 0.000 claims description 28
- 229940121354 immunomodulator Drugs 0.000 claims description 28
- 230000009261 transgenic effect Effects 0.000 claims description 23
- 238000012217 deletion Methods 0.000 claims description 22
- 230000037430 deletion Effects 0.000 claims description 22
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 21
- 238000007792 addition Methods 0.000 claims description 20
- 210000004602 germ cell Anatomy 0.000 claims description 20
- 238000003780 insertion Methods 0.000 claims description 20
- 230000037431 insertion Effects 0.000 claims description 20
- 229940012952 fibrinogen Drugs 0.000 claims description 18
- 229960002175 thyroglobulin Drugs 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 102000008946 Fibrinogen Human genes 0.000 claims description 14
- 108010049003 Fibrinogen Proteins 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 13
- 108010034949 Thyroglobulin Proteins 0.000 claims description 13
- 102000009843 Thyroglobulin Human genes 0.000 claims description 13
- 102000018358 immunoglobulin Human genes 0.000 claims description 13
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 11
- 230000001594 aberrant effect Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 9
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 9
- 230000000392 somatic effect Effects 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 230000006798 recombination Effects 0.000 claims description 6
- 238000005215 recombination Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000007503 antigenic stimulation Effects 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 111
- 102100021651 SUN domain-containing ossification factor Human genes 0.000 description 89
- 102000001301 EGF receptor Human genes 0.000 description 84
- 108060006698 EGF receptor Proteins 0.000 description 84
- 102000004169 proteins and genes Human genes 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 76
- 125000003275 alpha amino acid group Chemical group 0.000 description 59
- 239000000523 sample Substances 0.000 description 47
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 41
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 32
- 238000004519 manufacturing process Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 238000002649 immunization Methods 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 23
- 238000005734 heterodimerization reaction Methods 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 20
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 20
- 230000003013 cytotoxicity Effects 0.000 description 20
- 231100000135 cytotoxicity Toxicity 0.000 description 20
- 230000003053 immunization Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 16
- 239000012636 effector Substances 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 230000014616 translation Effects 0.000 description 16
- 230000006044 T cell activation Effects 0.000 description 15
- 108091008874 T cell receptors Proteins 0.000 description 15
- 235000018417 cysteine Nutrition 0.000 description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 102220080600 rs797046116 Human genes 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 229960000814 tetanus toxoid Drugs 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 9
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108010055044 Tetanus Toxin Proteins 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 229940118376 tetanus toxin Drugs 0.000 description 7
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000710 homodimer Substances 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229960001972 panitumumab Drugs 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000002096 anti-tetanic effect Effects 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 101100396606 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) iga gene Proteins 0.000 description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 4
- 241000282553 Macaca Species 0.000 description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229960005395 cetuximab Drugs 0.000 description 4
- 238000012761 co-transfection Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 101150117115 V gene Proteins 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229950009791 durvalumab Drugs 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940082789 erbitux Drugs 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 101150026046 iga gene Proteins 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000005588 Son of Sevenless Proteins Human genes 0.000 description 2
- 108010059447 Son of Sevenless Proteins Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 101150098203 grb2 gene Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000048776 human CD274 Human genes 0.000 description 2
- 102000045108 human EGFR Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- -1 proline amino acids Chemical class 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150093947 CD3E gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101001091242 Homo sapiens Immunoglobulin kappa joining 1 Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 102100034892 Immunoglobulin kappa joining 1 Human genes 0.000 description 1
- 101710117100 Immunoglobulin kappa variable 1-39 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 101710146340 T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 238000004224 UV/Vis absorption spectrophotometry Methods 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 208000011513 immunodeficiency 18 Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 108020001568 subdomains Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- GRVDJDISBSALJP-FIBGUPNXSA-N trideuterio($l^{1}-oxidanyl)methane Chemical group [2H]C([2H])([2H])[O] GRVDJDISBSALJP-FIBGUPNXSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650467P | 2018-03-30 | 2018-03-30 | |
| US62/650,467 | 2018-03-30 | ||
| PCT/NL2019/050199 WO2019190327A2 (en) | 2018-03-30 | 2019-03-29 | Multivalent antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3094318A1 true CA3094318A1 (en) | 2019-10-03 |
Family
ID=66349617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3094318A Pending CA3094318A1 (en) | 2018-03-30 | 2019-03-29 | Multivalent antibody |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11952424B2 (enExample) |
| EP (1) | EP3774885A2 (enExample) |
| JP (2) | JP7603578B2 (enExample) |
| KR (1) | KR20200139189A (enExample) |
| CN (1) | CN111936514A (enExample) |
| AR (1) | AR115320A1 (enExample) |
| AU (2) | AU2019243665B2 (enExample) |
| BR (1) | BR112020019795A2 (enExample) |
| CA (1) | CA3094318A1 (enExample) |
| EA (1) | EA202091871A1 (enExample) |
| IL (1) | IL277672A (enExample) |
| MA (1) | MA52212A (enExample) |
| MX (1) | MX2020010267A (enExample) |
| NZ (1) | NZ767923A (enExample) |
| PH (1) | PH12020551504A1 (enExample) |
| SG (1) | SG11202009036YA (enExample) |
| TW (1) | TW202003569A (enExample) |
| WO (1) | WO2019190327A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7603578B2 (ja) | 2018-03-30 | 2024-12-20 | メルス ナムローゼ フェンノートシャップ | 多価抗体 |
| MA54643A (fr) | 2018-12-31 | 2021-11-10 | Merus Nv | Multimères multivalents tronqués |
| EA202191448A1 (ru) | 2018-12-31 | 2021-11-19 | Мерус Н.В. | Смешанные связывающие домены |
| TW202039578A (zh) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
| CN114605546A (zh) * | 2019-03-29 | 2022-06-10 | 美勒斯公司 | Cd3结合分子 |
| NZ782091A (en) | 2019-05-09 | 2025-08-29 | Merus Nv | Variant domains for multimerizing proteins and separation thereof |
| JP7633259B2 (ja) | 2019-12-24 | 2025-02-19 | メルス ナムローゼ フェンノートシャップ | ＴＧＦ－βＲＩＩ結合タンパク質 |
| CN114945596A (zh) * | 2020-01-29 | 2022-08-26 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| JP2023526630A (ja) | 2020-05-21 | 2023-06-22 | メルス ナムローゼ フェンノートシャップ | Ｉｇ様分子の製造のための方法および手段 |
| US11692217B2 (en) * | 2020-11-11 | 2023-07-04 | Nautilus Subsidiary, Inc. | Affinity reagents having enhanced binding and detection characteristics |
| CN115536749A (zh) * | 2021-06-29 | 2022-12-30 | 三生国健药业（上海）股份有限公司 | 三特异性抗体、其制备方法和用途 |
| WO2023164510A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| MX2024010773A (es) * | 2022-03-03 | 2024-09-10 | Pfizer | Anticuerpos multiespecificos y usos de estos. |
| US20230383012A1 (en) * | 2022-04-13 | 2023-11-30 | Xencor, Inc. | Antibodies that bind pd-l1, pd-l2, and/or cd28 |
| WO2024144396A1 (en) | 2022-12-27 | 2024-07-04 | Merus N.V. | Method for generating bispecific proteins |
| AU2023415595A1 (en) * | 2022-12-30 | 2025-07-17 | Merus N.V. | Promiscuous cd3 binding molecules |
| CN117946245B (zh) * | 2023-02-23 | 2024-08-02 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2024206568A2 (en) * | 2023-03-31 | 2024-10-03 | Ibio, Inc. | Anti-cd3 antibodies |
| WO2025230409A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2025230410A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| EP1309705B1 (en) * | 2000-07-25 | 2012-02-15 | Immunomedics Inc. | Multivalent target binding protein |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2556747B1 (en) | 2008-06-27 | 2020-12-02 | Merus N.V. | Antibody producing transgenic mice |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| AU2010249470B2 (en) | 2009-05-20 | 2015-06-25 | Novimmune S.A. | Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants |
| PE20120540A1 (es) * | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| WO2011084255A2 (en) | 2009-12-17 | 2011-07-14 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| GB201000467D0 (en) * | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| JP2015527869A (ja) * | 2011-08-26 | 2015-09-24 | メリマック ファーマシューティカルズ インコーポレーティッド | タンデムＦｃ二重特異性抗体 |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| CA2870821C (en) | 2012-04-20 | 2022-06-14 | Merus B.V. | Methods and means for the production of ig-like molecules |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| LT2900694T (lt) * | 2012-09-27 | 2018-11-12 | Merus N.V. | Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai |
| EP2953974B1 (en) | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and bcma |
| MX2015010843A (es) | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Moleculas biespecificas de union al antigeno que activan celulas t. |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| DK3089994T3 (da) * | 2013-12-30 | 2022-07-04 | Epimab Biotherapeutics Inc | Fabs-in-tandem-immunglobulin og anvendelser deraf |
| JP6967853B2 (ja) | 2014-02-28 | 2021-11-17 | メルス ナムローゼ フェンノートシャップ | ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体 |
| WO2015130172A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| US20170306044A1 (en) | 2014-10-09 | 2017-10-26 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| ES2850325T3 (es) | 2014-10-09 | 2021-08-27 | Engmab Sarl | Anticuerpos biespecíficos contra CD3epsilon y ROR1 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| PL3115376T3 (pl) * | 2015-07-10 | 2019-01-31 | Merus N.V. | Ludzkie przeciwciało wiążące cd3 |
| HRP20200390T1 (hr) | 2015-08-03 | 2020-06-12 | Engmab Sàrl | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| SG11201803359VA (en) * | 2015-10-23 | 2018-05-30 | Merus Nv | Binding molecules that inhibit cancer growth |
| CA3022143A1 (en) | 2016-03-25 | 2017-09-28 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
| BR112018071276A2 (pt) * | 2016-04-27 | 2019-02-12 | Pfizer Inc. | anticorpos anti-il-33, composições, métodos e usos dos mesmos |
| JP7258556B2 (ja) | 2016-04-28 | 2023-04-17 | ビオミューネクス・ファルマシューティカル | Ｅｇｆｒ及びｈｅｒ２をターゲティングする二重特異性抗体 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| EP3515951B1 (en) | 2016-09-23 | 2024-02-28 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| CA3041254A1 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| IL266424B2 (en) | 2016-11-02 | 2023-09-01 | Engmab Sarl | A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma |
| US11780925B2 (en) * | 2017-03-31 | 2023-10-10 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene |
| CA3058341A1 (en) * | 2017-03-31 | 2018-10-04 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
| IL313753A (en) * | 2017-07-06 | 2024-08-01 | Merus Nv | Bispecific anti pd1-anti tim3 antibodies |
| CA3068929A1 (en) * | 2017-07-06 | 2019-01-10 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| AU2018297061B2 (en) * | 2017-07-06 | 2021-05-06 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
| SG11202001050PA (en) * | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
| EP3717008A1 (en) * | 2017-12-01 | 2020-10-07 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| JP7603578B2 (ja) | 2018-03-30 | 2024-12-20 | メルス ナムローゼ フェンノートシャップ | 多価抗体 |
| EA202191448A1 (ru) * | 2018-12-31 | 2021-11-19 | Мерус Н.В. | Смешанные связывающие домены |
| NZ782091A (en) * | 2019-05-09 | 2025-08-29 | Merus Nv | Variant domains for multimerizing proteins and separation thereof |
| PH12022551291A1 (en) * | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| CN114945596A (zh) * | 2020-01-29 | 2022-08-26 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
-
2019
- 2019-03-29 JP JP2021502692A patent/JP7603578B2/ja active Active
- 2019-03-29 NZ NZ767923A patent/NZ767923A/en unknown
- 2019-03-29 EP EP19721163.4A patent/EP3774885A2/en active Pending
- 2019-03-29 AU AU2019243665A patent/AU2019243665B2/en active Active
- 2019-03-29 MA MA052212A patent/MA52212A/fr unknown
- 2019-03-29 US US16/370,346 patent/US11952424B2/en active Active
- 2019-03-29 SG SG11202009036YA patent/SG11202009036YA/en unknown
- 2019-03-29 BR BR112020019795-5A patent/BR112020019795A2/pt unknown
- 2019-03-29 AR ARP190100836A patent/AR115320A1/es unknown
- 2019-03-29 KR KR1020207030642A patent/KR20200139189A/ko not_active Ceased
- 2019-03-29 CA CA3094318A patent/CA3094318A1/en active Pending
- 2019-03-29 EA EA202091871A patent/EA202091871A1/ru unknown
- 2019-03-29 CN CN201980023259.9A patent/CN111936514A/zh active Pending
- 2019-03-29 MX MX2020010267A patent/MX2020010267A/es unknown
- 2019-03-29 TW TW108111354A patent/TW202003569A/zh unknown
- 2019-03-29 WO PCT/NL2019/050199 patent/WO2019190327A2/en not_active Ceased
-
2020
- 2020-09-16 PH PH12020551504A patent/PH12020551504A1/en unknown
- 2020-09-29 IL IL277672A patent/IL277672A/en unknown
-
2023
- 2023-09-01 AU AU2023222983A patent/AU2023222983A1/en active Pending
-
2024
- 2024-02-13 US US18/440,607 patent/US20240352127A1/en active Pending
- 2024-02-13 US US18/440,582 patent/US20240360217A1/en active Pending
- 2024-08-16 JP JP2024136804A patent/JP2024161509A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020010267A (es) | 2020-11-06 |
| KR20200139189A (ko) | 2020-12-11 |
| TW202003569A (zh) | 2020-01-16 |
| AU2023222983A1 (en) | 2023-09-21 |
| EA202091871A1 (ru) | 2021-06-22 |
| AU2019243665B2 (en) | 2023-06-01 |
| US11952424B2 (en) | 2024-04-09 |
| AU2019243665A1 (en) | 2020-10-08 |
| BR112020019795A2 (pt) | 2021-01-05 |
| IL277672A (en) | 2020-11-30 |
| WO2019190327A8 (en) | 2021-06-17 |
| JP2024161509A (ja) | 2024-11-19 |
| EP3774885A2 (en) | 2021-02-17 |
| US20240352127A1 (en) | 2024-10-24 |
| AR115320A1 (es) | 2020-12-23 |
| WO2019190327A3 (en) | 2019-11-14 |
| CN111936514A (zh) | 2020-11-13 |
| US20190352401A1 (en) | 2019-11-21 |
| NZ767923A (en) | 2024-11-29 |
| JP7603578B2 (ja) | 2024-12-20 |
| MA52212A (fr) | 2021-02-17 |
| SG11202009036YA (en) | 2020-10-29 |
| JP2021519610A (ja) | 2021-08-12 |
| US20240360217A1 (en) | 2024-10-31 |
| PH12020551504A1 (en) | 2021-09-13 |
| WO2019190327A2 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240360217A1 (en) | Multivalent antibody | |
| JP7530299B2 (ja) | 抗ｃｄ３抗体及びその使用 | |
| CN113480656B (zh) | 抗ror1抗体 | |
| JP2023061969A (ja) | Ｓｉｒｐ－アルファドメインまたはそのバリアントを有する構築物 | |
| KR20220071263A (ko) | Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도 | |
| HK1217958A1 (zh) | 四价双特异性抗体 | |
| KR20220154757A (ko) | B7h4에 결합하는 항체 | |
| US20250236682A1 (en) | Antigen-binding protein comprising two fc domains and use thereof | |
| KR20200130723A (ko) | 항체 | |
| JP7440516B2 (ja) | 切断多価多量体 | |
| US20250206820A1 (en) | Ilt3 and cd3 binding agents and methods of use thereof | |
| US20240317862A1 (en) | Anti-b7-h3 monoclonal antibody and use thereof | |
| WO2024183637A1 (en) | Muc1 antibodies and methods of use | |
| US20250075002A1 (en) | MUC1 and CD16A Antibodies and Methods of Use | |
| JP2025542322A (ja) | Ｇｐｒｃ５ｄを標的とする多重特異性ポリペプチド複合物 | |
| KR20250156803A (ko) | 항-cd3 다중특이적 항체 및 사용 방법 | |
| HK40061499A (en) | Anti-ror1 antibodies | |
| JP2025528101A (ja) | 多重特異性ポリペプチド複合体 | |
| HK40083338A (en) | Antibodies binding to b7h4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |